Market Access Views & Analysis

Views & Analysis

Market Access

Crossed wires? Mixed messages on medicines

Leela Barham argues that the latest operational guidance for the NHS in England continues to illustrate a disconnect between the messages in big-ticket policy documents from the central gov

Market Access

Nine for 2023, part one: a reflection on inflection

The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one.

Market Access

Upholding regulatory compliance in decentralised trials

Before getting lost in the vast options a decentralised clinical trial (DCT) setup provides, sponsors considering a DCT model need to keep in mind that it is not a one-size-fits-all approac

Pharma Market Access

Pharma manufacturing can digitalise its way round the next c...

The turbulence of the last three years can make it seem as though pharma manufacturers have been operating in an atmosphere of non-stop crisis.

Digital

A few of 2022’s biggest pharma trends – the pharmaphorum pod...

As we close out the year, pharmaphorum's editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of

Sustainability